HIV Infections Clinical Trial
— ANC/FRSOfficial title:
Secondary Distribution of HIV Self-tests Through Antenatal and HIV Testing Services: a Pragmatic Cluster-randomized Trial (STAR-ANC)
A three arm cluster randomized trial randomizing government primary health clinics to a)
standard of care (SOC) with clinic invitation only; b) standard of care (SOC) and one
self-test kit to give to sexual partner (s); c) standard of care (SOC) and self-test kit and
monetary incentive given to partner conditional on clinic attendance and completion of
pre-set procedures to determine secondary accuracy.
Trial to be conducted in four districts (Blantyre, Zomba, Machinga and Chikwawa) in Malawi in
collaboration with the Ministry of Health.
Two primary outcomes:
1. proportion of male partners of antenatal care clinic attendees reported by the woman to
have tested for human immunodeficiency virus (HIV) within 28 days of enrolling the woman
2. Number of new HIV positives identified by providing trial services to newly tested HIV
positive clients in routine HIV testing service within 28 days of enrolling the index
client.
Data analysed as intention to treat with all eligible antenatal care (ANC) attendees and
index clients at each health facility as the denominator, with unpaired t-test used to
compare each intervention arm to the standard of care (SOC).
Status | Recruiting |
Enrollment | 10000 |
Est. completion date | April 30, 2019 |
Est. primary completion date | April 30, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion Criteria for clinics (cluster): - Government primary health clinic or centre - Provides antenatal care services, HIV testing services and HIV treatment services Exclusion Criteria for clinics: - Not a government health facility - Does not provide antenatal care services, HIV testing services and HIV treatment services - Not willing to be part of the trial Individual level eligibility screen for antenatal care attendees: - First antenatal care visit - Age 18 years or older - Has one main sexual partner (i.e. likely father) - Main sexual partner not already known to be HIV-positive and on antiretroviral therapy - Sexual partner likely to remain in clinic catchment area for the next 28 days - Not already tested together in this pregnancy [e.g. partner has come with her on this visit and has tested today] - Not already recruited in the study Individual level eligibility screen for index clients: - Age 18 years or older - At least one sexual partner not already known to be HIV-positive and on antiretroviral therapy - At least one sexual partner likely to remain in catchment area within the next 28 days - Not already recruited in the study |
Country | Name | City | State |
---|---|---|---|
Malawi | Mulanje District Hopsital | Mulanje |
Lead Sponsor | Collaborator |
---|---|
London School of Hygiene and Tropical Medicine | Liverpool School of Tropical Medicine, UNITAID, World Health Organization |
Malawi,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of partners tested for HIV | For antenatal care clinic attendees, this is as reported by the women during their next antenatal care visit | 28 days | |
Primary | Number of newly diagnosed HIV positive people | A count of number of sexual contacts of index HIV positive clients attending the clinic for post-test services | 28 days | |
Secondary | Proportion of partners of antenatal care clinic attendees who start HIV treatment, undergo circumcision, or attend discordant couples clinic | 28 days | ||
Secondary | Risk of adverse events (e.g. partnership breakdown, intimate partner violence, etc.) related to self-testing reported by antenatal care clinic attendees or HIV-positive index clients | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |